-
Uncategorized2 months ago
Novartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepen
AI heavyweight Anthropic has appointed Novartis CEO Vas Narasimhan to its board of directors as the link between the pharmaceutical industry and Silicon Valley deepens.
-
Uncategorized2 months agoOpinion: Hosting the ‘intellectual wrestling match’ between MAHA, public health
The deep distrust between public health and the Make America Healthy Again movement may seem impossible to heal. But the podcast “Why Should I Trust You?”...
-
Uncategorized2 months ago
Could biotech layoffs push life sciences talent to go global?
Amidst rising layoffs in key biotech hubs, global demand for specialized life sciences talent is driving a more borderless, distributed model of scientific work.
-
Uncategorized2 months ago
5 biopharma M&A deals where the workforce was the prize
Gilead, AstraZeneca and Vertex have acquired more than just a therapeutic asset in recent deals. BioSpace takes a look at five recent transactions where the staff...
-
Uncategorized2 months ago
Deep dive: Checking in with the FDA
BioSpace looks back at 2025 and where the FDA is going in 2026.
-
Uncategorized2 months ago
An inducible base editing platform for cancer functional genomics in vivo
Nature Biotechnology, Published online: 15 April 2026; doi:10.1038/s41587-026-03079-3 We developed a functional genomics platform using a small-molecule-controllable base editor that enables gene editing with reduced cellular...
-
Uncategorized2 months ago
Artificial allosteric protein switches with machine-learning-designed receptors
Post Content
-
Uncategorized2 months ago
Engineered Miniature CRISPR Boosts Gene‑Editing Efficiency in Human Cells
One of the biggest obstacles in targeting CRISPR therapy deliveries directly into the body isn’t the editing chemistry, it’s the size of the editors themselves. The...
-
Uncategorized2 months ago
CAR T Cell Therapy Biomanufactured by Cellares Infused Into First Two Patients
Cellares reported that the first two patients have been dosed with Cabaletta Bio’s investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) manufactured on Cellares’ Cell Shuttle...
-
Uncategorized2 months ago
Regeneron, Telix Launch Up-to-$4.3B Cancer-Focused Radiopharma Drug, Diagnostic Collaboration
Regeneron Pharmaceuticals plans to expand its pipeline into radiopharmaceutical therapies through an up to $4.3 billion collaboration with Telix Pharmaceuticals to co-develop and co-commercialize precision oncology...
Amgen shores up Tavneos’ FDA defense with Duke data analysis
